Menu Search
Equities

Nano Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3NQ:FRA

Nano Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.735
  • Today's Change0.005 / 0.68%
  • Shares traded40.00
  • 1 Year change-6.37%
  • Beta0.7108
Data delayed at least 15 minutes, as of Feb 06 2026 07:36 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nano Holdings Inc is a Japan-based company mainly engaged in the micellar nanoparticle technology to develop innovative pharmaceuticals, focusing on anticancer drugs that encapsulate small molecule drugs within nanoparticles. The Company operates through a single segment encompassing the research and development, manufacturing, and sales of pharmaceuticals and related services. The Company conducts non-clinical and early-stage clinical trials, then licenses the resulting development candidate assets to pharmaceutical companies, thereby developing an RNA drug discovery business that efficiently brings RNA medicines to the market. In promoting RNA drug discovery, the Company leverages its experience in drug delivery system anticancer drug development and manufacturing, nucleic acid drug research and development, and a variety of DDS selection options based on this experience, creating and licensing assets that enable rapid progress in pharmaceutical development.

  • Revenue in JPY (TTM)141.92m
  • Net income in JPY-757.17m
  • Incorporated1996
  • Employees20.00
  • Location
    Nano Holdings IncOhnoya Kyobashi Bldg., 1-4-10, KyobashiMINATO-KU 105-6226JapanJPN
  • Phone+81 364324791
  • Fax+81 364324794
  • Websitehttps://www.nanomrna.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.